control arm
The group in a trial that receives placebo or no treatment, serving as the comparison against the treatment group
As defined in The Good, the Bad, and the Ugly of the Covid Vaccine (with Vinay Prasad)
Where it comes up · 4
- Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant5 claims
- Bridging Science, Medicine, and Returns2 claims
- Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty1 claim
- The Good, the Bad, and the Ugly of the Covid Vaccine (with Vinay Prasad)1 claim
Most important claims · 9 of 9Search all claims for “control arm” →
- By allowing studies without control arms, inadequate control arms, or surrogate endpoints like tumor shrinkage, the FDA creates a bar that is hard for small entrants to clear while making it easy to sustain lofty prices—producing a system that benefits large corporations and penalizes small entrepreneurs without guaranteeing the product works.Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty
- AI tools are rapidly commoditizing drug discovery, for example AlphaFold protein structure prediction and lipid nanoparticle formulation, but clinical development remains behind because there is no holistic model of a human being and putting drugs in people remains the gold standard.Bridging Science, Medicine, and Returns
- Better prediction of natural outcomes from high-quality big data sets lets machine learning predict control-arm outcomes, which is making trials shorter and smaller, though the gold standard remains putting a drug in people.Bridging Science, Medicine, and Returns
- Idealized clinical trials enroll younger, healthier patients with fewer comorbidities than real-world patients, so trial survival overstates real-world benefit; in some cases real-world patients on the active drug live half as long as control-arm patients on a sugar pill in the trial, meaning the true absolute benefit of these agents is even smaller than the published figures.Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant
- When the difference between a p-value of 0.49 and 0.51 is $10 billion in expected revenue, companies will do everything legally permitted to win: choose the weakest comparator drug, run trials in settings with no further therapy after progression to exaggerate differences, enroll younger healthier populations, and skew dose-reduction rules to penalize the competitor—so as long as something is not explicitly prohibited, the incentive guarantees the thumb goes on the scale.Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant
- Some cancer drugs are not merely marginal but actually ineffective—they appear marginal only in the contrived trial setting where they are tested against a weak control arm that is not standard of care, with a flawed design, in an atypical population—so in real-world use they probably do not work at all.Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant
- Of 100 consecutive oncology drug approvals, only about a third improve overall survival or quality of life; a third merely delay progression-free survival, which only gives the illusion of being meaningful because it rests on arbitrary radiographic cut-offs; and a third are approved on single-arm studies with no control arm using response rate—so approving drugs on these surrogate endpoints means many likely do not improve survival or quality of life.Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant
- Running separate randomized trials by age cohort (nursing homes powered for mortality, 60-80 for severe disease, younger groups for transmission) rather than one 18-100 study would have allowed younger cohorts' trials to run longer without crossover, preserving the ability to detect waning efficacy and safety signals—feasible because supply constraints meant the elderly got the vaccine first anyway.The Good, the Bad, and the Ugly of the Covid Vaccine (with Vinay Prasad)
- The FDA is legally free to decline approval for drugs tested only against a control arm that is not best practice or relevant standard of care, since such a 'horse race' is rigged, yet over the last 20-30 years it has drifted consistently toward saying yes; it should simply refuse to approve drugs based on such flawed trials.Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant